Why the study?
How should antiplatelet and anticoagulant therapy be combined in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention?
How should antiplatelet and anticoagulant therapy be combined in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This review discusses European approaches to combining antiplatelet and anticoagulant therapy in patients with AF and ischemic heart disease, including insights from the ARISTOTLE subanalysis.
Up-to-date European approaches to the management of patients with atrial fibrillation (AF) after acute coronary syndrome and/or percutaneous coronary interventions are considered. Features of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic events) are discussed. The authors briefly present subanalysis of ARISTOTLE study, which compares the efficacy and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Напалков et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: